Table 1:
Increased dose darunavir/ritonavir subjects: demographic characteristics and outcomes (n=24).
| Maternal characteristics | N(%) or median (IQR) |
|---|---|
| Age at delivery (years) | 26.9 (21.4, 34.4) |
| Weight at delivery (kg) | 86.2 (68.4, 95.7) |
| Race/Ethnicity | |
| Asian, Pacific Islander | 1 (4%) |
| Black Non-Hispanic | 12 (50%) |
| Hispanic (Regardless of Race) | 11 (46%) |
| Duration of darunavir before PK evaluations (weeks) | |
| Before 2nd trimester PK evaluations | 149 (64.9, 262.1) |
| Before 3rd trimester PK evaluations | 102.1 (26.0, 190.4) |
| Number of mothers taking concomitant ARVS at the time of 3rd pharmacokinetic evaluations | *FTC 15; TDF 15; ZDV 4; 3TC 3; RAL 5; RPV 2; DTG 3; ATV 2; ENF 1. |
| Second trimester | |
| Gestational age (weeks) | 23.9 (23.1, 24.7 ) |
| Number of mothers with viral load ≤50 copies/mL | 6 (66.7%) |
| CD4 (cells/mm3) | 682 (300, 761) |
| Third trimester | |
| Gestational age (weeks) | 33.5 (32.5, 34.4) |
| Number of mothers with viral load ≤50 copies/mL | 21 (87.5%) |
| CD4 (cells/mm3) | 537.5 (303, 910.5) |
| Delivery | |
| Number of mothers with viral load ≤50 copies/mL | 20 (80%) |
| CD4 (cells/mm3) | 506 (338, 786) |
| Postpartum | |
| Weeks post-delivery (weeks) | 2.8 (2.4, 3.2) |
| Number of mothers with viral load ≤50 copies/mL | 17 (70.8%) |
| CD4 (cells/mm3) | 652.5 (395, 910.5) |
| Pregnancy outcomes | |
| Gestational age (weeks) | 39 (38.1, 39.6) |
| Birth weight (grams) | 3118 (2770, 3405) |
| Infection status | 20 uninfected/4 indeterminate |
*
ARVs (Antiretrovirals), FTC (emtricitabine), TDF (tenofovir disoproxil fumarate), ZDV (zidovudine), 3TC (lamivudine), RAL (raltegravir), RPV (rilpivirine), ATV (atazanavir); ENF (enfuvirtide) and DTG (dolutegravir).
Interquartile ranges (IQR) are in brackets.